For the first time, we can see how these proteins are organized
For nearly four decades, a fundamental protein governing how cells grow, survive, and communicate remained structurally invisible to science — close enough to study in fragments, too elusive to fully understand. Researchers at Mayo Clinic have now mapped the complete molecular architecture of protein kinase C beta, revealing not only how the protein activates inside the body but how a breast cancer drug called endoxifen quietly dismantles it through an entirely novel mechanism. The discovery, born from the simple but consequential decision to grow human proteins in human cells, transforms an incomplete blueprint into a working map — one that may guide precision therapies for cancer, Alzheimer's disease, and conditions not yet linked to this protein family.
- A protein central to cell communication had resisted full structural mapping since its discovery in the 1980s, leaving drug designers working from dangerously incomplete pictures.
- The breakthrough came when Mayo Clinic's team abandoned decades of standard practice and produced PKCβ in human cells rather than insect cells, yielding material stable and clean enough to finally reveal the enzyme's true architecture.
- The structural data exposed a hidden mechanism: membrane lipids act as a molecular lever, physically flipping PKCβ from dormant to active — a process long suspected but never clearly seen.
- Endoxifen, a breast cancer drug with poorly understood effects, was found to inhibit PKCβ not by blocking its active site but by reshaping the protein from a distance, ultimately triggering its destruction — a fundamentally different approach from all prior PKC inhibitors.
- Mayo Clinic is now moving on multiple fronts: clinical trials of endoxifen in premenopausal breast cancer patients and a structural expansion to all ten members of the PKC protein family, each a potential target for cancer, Alzheimer's, and beyond.
For nearly forty years, scientists have worked from an incomplete picture of protein kinase C beta — a molecular switch so central to how cells grow and communicate that understanding it could reshape treatment for cancer, Alzheimer's disease, and more. Mayo Clinic researchers have finally resolved that picture. Their findings, published in Nature Communications, reveal the full architecture of PKCβ and explain, for the first time, how the breast cancer drug endoxifen manages to shut it down.
Protein kinase C is not a single protein but a family of ten, each acting as a switch that tells cells whether to grow, survive, or change behavior. Because these switches malfunction across so many diseases, they have long been considered ideal drug targets — but no one could see them clearly enough to design precise therapies. The problem was methodological: standard laboratory techniques produced proteins that looked nothing like their natural human counterparts.
Matthew Schellenberg's team at Mayo Clinic solved this by growing PKC enzymes in human cells rather than the insect cells that had been the field's default for decades. The resulting material was stable and clean enough to finally show how PKCβ organizes and regulates itself. What they found was a protein that exists in two states — closed and dormant, or open and active — with membrane lipids acting as a molecular lever that physically triggers the switch.
The team also traced exactly how endoxifen inhibits PKCβ. Rather than blocking the protein's active site directly, the drug works through an allosteric mechanism — reshaping the protein from a distance, stabilizing it at the cell membrane in a way that ultimately triggers its destruction. This distinguishes endoxifen from every prior PKC inhibitor and likely explains why it produces biological effects that earlier compounds could not.
Mayo Clinic is already expanding the work: testing endoxifen in premenopausal women with estrogen receptor-positive breast cancer and planning structural analysis of all ten PKC family members. Each one carries its own role in disease, and researchers can now begin asking which should be activated or inhibited in which context. The forty-year mystery is resolved — and the more precise work of building therapies from it has only just begun.
For nearly forty years, scientists have stared at a locked door. Inside that door lay the complete molecular structure of protein kinase C beta—a protein so fundamental to how cells communicate that understanding it could reshape how we treat cancer, Alzheimer's disease, and a dozen other conditions. Mayo Clinic researchers have finally turned the key. Their findings, published in Nature Communications, reveal not just the architecture of PKCβ, but how a breast cancer drug called endoxifen manages to shut it down—a mechanism that differs fundamentally from every other PKC inhibitor ever tested.
Protein kinase C is actually a family of ten related proteins, each one a molecular switch that tells cells whether to grow, survive, or change behavior. Because these switches malfunction in so many diseases, researchers have long known they represent ideal drug targets. The problem was that no one could see them clearly enough to design precision therapies. When PKC was first discovered in the 1980s, scientists lacked the tools to map the full structure of these enzymes as they exist in human bodies. Traditional laboratory methods produced proteins that looked nothing like their natural counterparts, leaving researchers working from incomplete blueprints.
Matthew Schellenberg and his team at Mayo Clinic solved this by changing where they grew the proteins. Instead of using insect cells—the standard approach for decades—they produced human PKC enzymes in human cells. The difference was transformative. The resulting material was clean enough, stable enough, to finally reveal how PKCβ1 and PKCβ2 actually organize themselves. "By producing the protein in human cells, we were able to obtain high-quality material that enabled us to finally see how this enzyme is organized and regulated," Schellenberg explained. The view they got was revelatory.
What they saw was a protein that exists in two states: closed and inactive, or open and switched on. The trigger for that switch had long puzzled researchers. They knew that when PKCβ encountered the lipid membranes inside cells, something happened—the protein activated. But how? The structural data showed the mechanism with crystalline clarity. Membrane lipids act like a molecular lever, physically shifting the enzyme from its dormant configuration to an active one, exposing the site where it does its work. It was elegant and simple once you could see it.
Then came the question of endoxifen, a drug already known to have effects on breast cancer cells but whose mechanism remained mysterious. Using structural biology combined with biochemical and cellular studies, the Mayo team traced exactly how endoxifen inhibits PKCβ. The drug does not block the active site directly. Instead, it works through what researchers call an allosteric mechanism—it changes the protein's shape and behavior from a distance, stabilizing PKCβ at the cell membrane in a way that ultimately triggers the protein's destruction. This is fundamentally different from previous PKC inhibitors, which is likely why endoxifen shows biological effects that earlier compounds did not. "That distinction may help explain why endoxifen shows biological effects that earlier compounds did not," said Matthew Goetz, a medical oncologist at Mayo Clinic.
The implications ripple outward. The PKC family contains ten members, each with its own role in health and disease. Some may promote tumor growth while others suppress it. For decades, determining which protein should be activated or inhibited in which context has remained unanswered. Now researchers have a framework. They can ask sophisticated questions about how different PKC proteins contribute to cancer and design drugs that target the right protein in the right situation. Mayo Clinic is already moving forward on multiple fronts: studying endoxifen in premenopausal women with estrogen receptor-positive breast cancer, investigating whether its effects on PKCβ explain its anticancer activity, and planning to expand the structural analysis to all ten PKC family members.
What opened at Mayo Clinic was not just a scientific door but a methodological one. For the first time, researchers can see how these proteins are organized, how they function, and how they might be targeted with precision. That understanding could guide the next generation of therapies—not just for breast cancer, but for Alzheimer's, lymphoma, colorectal cancer, and conditions we have not yet connected to PKC dysfunction. The forty-year mystery is solved. The real work is just beginning.
Citações Notáveis
By producing the protein in human cells, we were able to obtain high-quality material that enabled us to finally see how this enzyme is organized and regulated.— Matthew Schellenberg, molecular biologist at Mayo Clinic
This mechanism is fundamentally different from previous PKC inhibitors that have been tested over the years. That distinction may help explain why endoxifen shows biological effects that earlier compounds did not.— Matthew Goetz, medical oncologist at Mayo Clinic
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take forty years to see this protein's structure? Wasn't the technology there earlier?
The technology existed, but the approach was wrong. Scientists were growing these proteins in insect cells, which produced versions that didn't behave like the real thing in human bodies. It's like studying a car engine by looking at a toy model. The breakthrough was realizing they needed to grow PKC in human cells to see its true form.
And that changed everything?
Completely. Once they could see the actual structure, they could finally understand how the protein switches on and off. They discovered that lipid membranes act like a physical lever—they literally reshape the protein from closed to open. That's the kind of detail you can't guess at. You have to see it.
What makes endoxifen different from other drugs that tried to target PKC?
Most inhibitors try to jam up the active site directly, like putting a wedge in a lock. Endoxifen works differently. It stabilizes the protein in a way that causes its own destruction. It's more elegant and apparently more effective, which is why it's showing promise in breast cancer patients.
So this is just about one protein?
No, that's the larger story. PKC is actually a family of ten proteins. Understanding PKCβ gives researchers a template for understanding the others. Each one might have a different role in disease, so the real precision medicine comes from learning which protein to target in which disease.
What happens next?
Mayo is testing endoxifen in actual patients right now and mapping the structures of the other nine PKC proteins. If they can understand each one the way they understand PKCβ, they could design drugs that hit specific targets in Alzheimer's, lymphoma, colorectal cancer—diseases where PKC dysfunction plays a role but we've never had the tools to address it precisely.